Fibrosis
AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
Published in Drug Law Weekly, March 20th, 2007
AOP Orphan Pharmaceuticals AG ("AOP Orphan") and Lantibio, Inc. ("Lantibio") announced positive final results from their placebo controlled, double-blinded Phase II clinical study of Moli1901, an experimental compound to treat cystic fibrosis ("CF"). Moli1901 is being developed by AOP Orphan in Europe under a licensing and commercialization agreement with Lantibio. The study, performed at multiple centers in Europe, was designed to investigate safety and tolerability of aerosolized Moli1901 in adolescents (12 years of age or older) and adults with CF.
The study was first populated with 9 subjects aged 16 years and older (Phase I), followed with 9 subjects aged 12-16...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2007-03-20)
More Articles from Drug Law Weekly
- Autism
Study data from Liverpool School of Tropical Medicine update understanding of autism in children - Clinical Trials Research
Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP by Department of Health and Human Services - Drug Development
Fox Chase Cancer Center and Cancer Research Technology Inc. Initiate Drug Discovery Collaboration - Drug Safety
Taking the wraps off drug safety data from clinical trials - Heart Attack
N.J. VIOXX Product Liability Trial Proceeds to Second Phase - Mental Disorders Therapy
New mental disorders therapy study results from Netherlands Institute of Mental Health and Addiction described - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
